ModifiedColorado Rocky Mountain Health PlansPolicy CS355OH.D

Surgery for the Prevention and Treatment of Lymphedema (for Ohio Only)

Defines coverage stance for surgical procedures intended to prevent or treat lymphedema for members in Ohio; applies to requests evaluated under Ohio Administrative Code 5160-101.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicySurgery for the Prevention and Treatment of Lymphedema (for Ohio Only)

Policy CodePolicy CS355OH.D

Change TypeCode addition

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionInclude CPT 1019T in prior authorization and ensure documentation aligns with Ohio Medicaid/contractual requirements.

SourceLink

POLICY UPDATE CHANGES

Added CPT code 1019T to the list of applicable codes.

Ohiojurisdiction

Insufficient evidencecoverage rationale summary

1CPT code added in this revision

Multiplenamed surgical techniques considered

Coverage Criteria and Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Not medically necessary — surgical lymphedema procedures

Covered when ALL of the following are met

Primary coverage stance: Surgical procedures for the prevention or treatment of Lymphedema are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Includes but not limited to Axillary Reverse Mapping (ARM); Liposuction/Lipectomy; Microsurgical treatments such as Lymphaticovenous Anastomosis/lymphovenous bypass; Vascularized Lymph Node Transfer.

inv-02: Liposuction/Lipectomy (reductive)

Reductive surgery (lipoaspiration/liposuction) — considered when ALL of the following are met:

Reductive surgery criteria: 1) Patient has moderate-to-severe, nonpitting lymphedema (typically Stage II–III); 2) Symptoms refractory to an adequate trial of conservative therapy (controlled compression therapy or complex decongestive therapy); 3) Procedure will be followed by controlled compression therapy (lifelong compression as indicated); 4) Patient counseled that evidence is low-quality and the procedure has potential but unproven benefit for limb volume reduction and decreased infection risk.

Derived from Hayes HTA and systematic reviews describing lipoaspiration plus compression therapy outcomes

inv-03: Lymphaticovenous anastomosis (LVA) and Vascularized Lymph Node Transfer (VLNT)

Microsurgical physiologic procedures (LVA, VLNT) — considered when ALL of the following are met:

Microsurgical procedure criteria: 1) Documented secondary (or selected primary) lymphedema with clinical impairment; 2) Prior inadequate response to standard nonsurgical therapies (e.g., compression, manual lymphatic drainage, pneumatic devices, supervised exercise); 3) Preoperative assessment documents viable lymphatic vessels (for LVA) or suitable donor and recipient anatomy (for VLNT); 4) Patient informed that existing evidence is heterogeneous and generally low quality with potential but unproven benefit; 5) Surgical planning and postoperative care include continued use of compression/manual drainage as used in reported series.

Based on systematic reviews, meta-analyses, and ECRI/Hayes assessments showing pooled clinical improvement but low-quality evidence and heterogeneity

inv-04: Immediate Lymphatic Reconstruction / LYMPHA (preventive)

Immediate lymphatic reconstruction / LYMPHA — considered when ALL of the following are met:

Preventive microsurgery criteria: 1) Patient is undergoing oncologic lymph node dissection and ILR/LYMPHA is technically feasible; 2) Surgeon documents ability to perform lymphatic anastomoses (number of bypasses performed and recipient vein suitability); 3) Patient informed that trials show reduced incidence of lymphedema at 12–24 months in some studies but long-term durability and generalizability are uncertain; 4) Consider potential oncologic concerns for groin/inguinal procedures and acknowledge limited data regarding recurrence risk; 5) Procedure planning and follow-up include standardized limb volume/bioimpedance/ICG measurement and documentation as used in trials.

Derived from Hayes HTA, randomized trial interim reports, and systematic reviews showing reduced BCRL incidence but limited long-term data and heterogeneity

inv-05: Covered with clinical criteria and specialist requirements

Coverage considerations derived from the evidence and guideline statements in the document fragments:

Prophylactic microsurgical procedures (ILR/LYMPHA/LVA) for prevention of lymphedema: Multiple systematic reviews and meta-analyses report reduced incidence of lymphedema after immediate lymphatic reconstruction or prophylactic LVA during oncologic lymph node dissection, but evidence is limited by heterogeneous, low-quality studies and short follow-up; NICE recommends LVA only with special arrangements for governance, consent and audit/research.evidence conditional

See systematic reviews and NICE guidance

Therapeutic microsurgical procedures (LVA, VLNT) for established lymphedema: Consensus guidance (AAPS, ISL) supports use of LVA and VLNT to reduce severity in selected patients, with better outcomes in earlier-stage disease; procedures are not curative and selection should occur at specialized centers with experienced microsurgeons.selected patients after evaluation

See AAPS and ISL consensus statements

The policy states that surgical procedures for the prevention or treatment of lymphedema are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy. Named examples include Axillary Reverse Mapping (ARM), Liposuction/Lipectomy, microsurgical treatments (lymphaticovenous anastomosis / lymphovenous bypass), and vascularized lymph node transfer. Coverage determinations should reflect this overall stance unless specific, high-quality evidence and documented patient selection criteria justify exception.

The document raises specific oncologic safety concerns for performing lymphaticovenous anastomosis (LVA) in the groin/inguinal region after inguinal lymph node dissection. A retrospective series reported higher recurrence rates and shorter recurrence‑free and metastasis‑free survival in the small group receiving immediate groin LVA compared with controls, prompting concern that lymphatic manipulation in this setting could theoretically facilitate tumor spread. These findings are limited by small numbers and require cautious application of preventive LVA for lower‑extremity cancers.

The policy emphasizes that available evidence for LVA, VLNT, LYMPHA and related microsurgical procedures is predominantly low quality, heterogeneous, and short‑term. Systematic reviews and Cochrane analyses conclude that while some trials and case series report reduced lymphedema incidence or symptom improvement, the overall certainty of benefit is limited and does not support widespread adoption outside controlled or specialist settings. NICE and evidence analyses recommend these procedures only with appropriate clinical governance, audit, or research arrangements.

Reviewers and prior authorization staff should consult the full policy text and the governing federal, state (Ohio Administrative Code) and contractual requirements when making coverage determinations. The policy is intended as a standard reference but state or contractual rules govern in the event of conflict, and documentation of imaging, prior conservative therapy, and specialist governance may be required to evaluate requests.

Named surgical techniques discussed in the policy include: Axillary Reverse Mapping (ARM); Liposuction / Lipectomy; Lymphaticovenous Anastomosis (LVA) / Lymphovenous bypass; Vascularized Lymph Node Transfer (VLNT); Immediate Lymphatic Reconstruction (LYMPHA / ILR). The policy also lists applicable CPT codes (for reference), including newly added CPT 1019T.

The body of evidence is characterized throughout as low quality, heterogeneous, and limited in duration. Systematic reviews and meta‑analyses identify potential benefits (e.g., reduced limb volume or incidence) but note methodological limitations, small sample sizes, and variable outcome reporting that reduce confidence in conclusions.

Across preventive and therapeutic indications, the policy concludes there is insufficient high‑quality evidence to support routine use of LVA or VLNT for prevention or treatment of lymphedema. While some studies report clinical improvement or reduced incidence, limitations in study design and aggregation mean benefits remain potential but unproven for most patients.

This excerpt does not contain any separate commercial exclusion lists. For final benefit determinations and explicit exclusion language, reviewers must consult the complete policy and applicable federal, state (OAC) or contractual coverage documents.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Submit clinical documentation demonstrating medical necessity and that conservative therapies were attempted and failed when applicable. Benefit determination is subject to state-specific rules (Ohio Administrative Code 5160-101) and the member's contract; in case of conflict, federal, state, or contractual requirements govern.

Prior authorization required for surgical lymphedema procedures (e.g., liposuction, LVA, vascularized lymph node transfer, LYMPHA/ILR).
Include operative reports, pre- and post-operative limb measurements/volumes, imaging (e.g., ICG lymphangiography, near-infrared fluorescence), and documentation of device use when applicable. (See applicable codes and added CPT 1019T).
Document prior conservative therapy: CDT, compression garment use, manual lymphatic drainage, pneumatic compression, and supervised exercise; include duration and response. For reductive procedures (liposuction), show failure of compression/CDT.
For preventive procedures (ILR/LYMPHA) include indication, intraoperative findings, number/type of anastomoses, surgeon expertise, and governance/consent for research or audit when required.
Specialist/surgeon and facility expectations: high-volume center with microsurgical expertise; multidisciplinary team involvement for patient selection and perioperative care.

Denial Risk

Denial Risk — Not Medically Necessary / Evidence Limitations

Surgical procedures for lymphedema are considered unproven and may be denied if documentation does not support medical necessity or if selection criteria are not met. Providers should be aware that evidence limitations for some procedures (e.g., liposuction, LVA, lymph node transfer) may lead to noncoverage determinations.

Procedures commonly considered unproven: ARM, liposuction/lipectomy (unless strict criteria and documentation met), microsurgical treatments including LVA/LVB and vascularized lymph node transfer.
NICE recommends special arrangements (governance, consent, audit/research) for LVA during node dissection; lack of these arrangements may increase denial risk.
Evidence for liposuction is limited and generally considered potential but unproven benefit; adequate documentation of prior failed conservative therapy and long-term follow-up is expected.

Documentation Required

Documentation Requirements

Provide thorough documentation to support coverage decisions. Include baseline and follow-up objective measurements, imaging reports, and clear operative details. Maintain records of multidisciplinary evaluation and informed consent.

Baseline and follow-up limb volume or circumference measurements (method and dates) and patient-reported outcome measures.
Imaging: ICG lymphangiography or near-infrared fluorescence reports used for selection and intraoperative planning; include FDA device references when applicable.
Operative documentation: indication, technique, number and type of anastomoses or grafts, intraoperative confirmation of patency, and postoperative plan including compression therapy.

Step Therapy

Conservative Therapy Expectation

Conservative therapy is expected prior to consideration of reductive or complex surgical procedures unless contraindicated. Document duration, adherence, and objective lack of response to conservative measures.

Required conservative measures typically include a trial of complete decongestive therapy (CDT) or controlled compression therapy (CCT) with documented adherence and clinical response.
For liposuction/lipectomy, demonstrate nonpitting, fibrotic or fatty predominant lymphedema not responsive to sustained compression and CDT; include staging (e.g., ISL Stage II/III) and rationale for surgical approach.

Billing Rule

Coding and Benefit Determination Note

Coding must be accurate and is used for benefit determination only. Inclusion of a code in the policy does not guarantee coverage. Newly added CPT code 1019T should be included on requests when applicable.

List and attach all relevant CPT/ICD-10 codes on prior authorization requests; inclusion in policy is for reference and not a coverage guarantee.
Added CPT 1019T effective 04/01/2026 — include when applicable to submissions.

Definitions and Terminology

inv-34: Axillary Reverse Mapping

DefinitionA technique that injects blue dye in the upper extremity to allow visualization and preservation of lymphatic channels and lymph nodes during axillary lymph node dissection.

Primary usePerformed during axillary lymph node dissection to identify and attempt preservation of upper-extremity lymphatics.

Policy stanceListed among surgical procedures for prevention/treatment of lymphedema that are considered unproven and not medically necessary in this policy.

Reference guidanceSystematic reviews/meta-analyses have evaluated ARM but overall policy cites insufficient evidence for routine use.

inv-35: Liposuction/Lipectomy

DefinitionA procedure that uses vacuum suction to remove subcutaneous adipose tissue in certain anatomical areas (reducing nonfluid/fat component of chronic nonpitting lymphedema).

Indications reportedUsed for moderate-to-severe, nonpitting primary or secondary lymphedema (often Stage II–III) refractory to conservative therapies.

Evidence summaryLow-quality evidence suggests liposuction plus controlled compression therapy is associated with greater limb size reduction and lower infection risk versus conservative therapy alone.

Postoperative requirementProcedure is performed with expectation of lifelong/ongoing compression therapy and multidisciplinary care.

inv-36: Lymphaticovenular/Lymphaticovenous Anastomosis

DefinitionA surgical procedure that connects small lymphatic vessels to adjacent venules to shunt excess lymphatic fluid (lymphaticovenular/lymphaticovenous anastomosis).

Intended effectRestore or improve lymphatic drainage to reduce limb circumference/volume and infection frequency in selected patients.

Evidence summarySystematic reviews/meta-analyses report pooled clinical improvement (overall ~36%); evidence heterogeneous and generally low quality — benefit is potential but unproven.

inv-37: Lymphedema

DefinitionThe build-up of fluid in soft body tissues when the lymph system is damaged or blocked.

Clinical featuresCan be primary or secondary; presents with limb swelling, risk of infection, and progressive fat/fibrotic changes (nonpitting in chronic disease).

First-line managementConservative therapy (complete decongestive therapy: compression, manual lymphatic drainage, skin care, exercise) is standard prior to surgical approaches.

inv-38: Vascularized Lymph Node Transfer

DefinitionA surgical procedure that transfers skin, fat, and lymph nodes for lymphatic reconstruction (vascularized lymph node transfer).

Intended outcomeRestore lymphatic drainage to reduce lymphedema severity; reported improvements in limb volume and infection frequency in selected studies.

Evidence and guidanceEvidence (systematic reviews/meta-analyses) suggests VLNT can reduce severity (AAPS grade supportive); overall evidence variable and not curative.

inv-39: Reductive surgery (lipoaspiration/liposuction)

DefinitionDebulking surgical removal of subcutaneous tissue (lipoaspiration/liposuction) to reduce the nonfluid/fat component of chronic nonpitting lymphedema.

Typical patient selectionPatients with chronic, nonpitting lymphedema (moderate-to-severe) who have not responded adequately to conservative therapy.

Key requirementProcedure is typically followed by controlled compression therapy; lack of adequate conservative therapy trial may preclude approval.

inv-40: Physiologic microsurgical procedures

DefinitionProcedures aiming to restore lymphatic drainage (e.g., LVA, VLNT) that re-establish physiologic lymph flow via microsurgical techniques.

Patient selectionConsidered for secondary lymphedema after inadequate response to nonsurgical therapies; better outcomes reported in earlier-stage disease.

Evidence summarySystematic reviews report pooled clinical improvements but with heterogeneity and generally low-quality evidence; benefits are potential but unproven for routine use.

inv-41: Immediate lymphatic reconstruction (ILR) / LYMPHA

DefinitionPreventive microsurgical lymphatic anastomosis performed at the time of oncologic lymph node dissection (also called LYMPHA or ILR) intended to reduce subsequent risk of secondary lymphedema.

Reported outcomesSome studies/meta-analyses report reduced incidence of breast cancer-related lymphedema at 1–3 years, but overall evidence is low quality and long-term durability is uncertain.

Selection and documentationTypically considered when ILR is technically feasible and surgeon can document ability to perform anastomoses; potential oncologic concerns in groin/inguinal procedures warrant caution.

inv-42: Immediate lymphatic reconstruction (ILR) / LYMPHA (alt reference)

Alternate termLYMPHA is also described as lymphatic microsurgical preventive healing approach or immediate lymphatic reconstruction (ILR) performed during nodal dissection.

Evidence highlightsMeta-analyses report pooled low incidence rates (e.g., 2.75%–5.15% for upper extremity after ALND with ILR/PLS) in observational cohorts but studies are heterogeneous.

Policy considerationAlthough promising, ILR/LYMPHA is supported by low-quality evidence and requires specialized centers and standardized techniques before routine adoption.

inv-43: Lymphaticovenular anastomosis (LVA)

DefinitionMicrosurgical anastomosis connecting lymphatic channels to venules (LVA) to improve lymphatic drainage and reduce lymphedema severity.

Typical procedure detailStudies report mean number of anastomoses (e.g., ~3.39 for upper extremity, ~4.50 for lower extremity) and require identification of viable lymphatics preoperatively (ICG/near-infrared imaging).

Evidence noteSystematic reviews/meta-analyses indicate clinical improvement after LVA but evidence heterogeneity and limitations reduce certainty of benefit.

inv-44: Vascularized lymph node transfer (VLNT)

DefinitionTransfer of vascularized lymph node-containing tissue flaps (VLNT) to the affected region to restore lymphatic drainage and reduce lymphedema severity.

Outcomes variabilityPooled analyses show greater clinical improvement with VLNT than LVA in many studies; outcomes vary by donor flap type (e.g., gastroepiploic vs submental).

GuidanceAAPS and ISL guidance support VLNT in selected patients but emphasize specialist centers and that procedures are not curative; evidence quality varies.

inv-45: Liposuction (lymphatic liposuction / lipoaspiration)

DefinitionLiposuction (lymphatic liposuction / lipoaspiration) is a debulking procedure to remove the nonfluid/fat component of chronic nonpitting lymphedema.

Clinical contextUsed when conservative measures fail; combined with lifelong compression and multidisciplinary team management.

Evidence and expectationsLow-quality evidence suggests benefit for limb volume reduction and infection risk reduction when combined with compression; adequate trial of conservative therapy is expected prior to consideration.

inv-46: LYMPHA / Immediate lymphatic reconstruction

DefinitionLYMPHA / Immediate lymphatic reconstruction: a microsurgical preventive approach performed during nodal dissection intended to reduce incidence of postoperative lymphedema.

Reported benefitsSome trials and meta-analyses report statistically significant reductions in BCRL incidence at 1–3 years, though overall evidence is low quality and generalizability is uncertain.

Operational requirementTechnical feasibility, surgeon documentation of anastomoses, and specialist center experience are emphasized for candidate selection and reporting.

inv-47: Lymphovenous anastomosis (LVA) (definition/alt)

DefinitionLymphovenous anastomosis (LVA): microsurgical connections between lymphatic vessels and veins for treatment or prevention of lymphedema.

Clinical metricsSystematic reviews report pooled clinical improvement for LVA (upper extremity ~29.4% improvement) though heterogeneity and reporting limitations exist.

Policy viewEvidence is promising but heterogeneous and of low quality; procedures should be performed in specialized settings and are not established routine care.

inv-48: Vascularized lymph node transfer (VLNT) (definition/alt)

DefinitionVascularized lymph node transfer (VLNT): transfer of lymph node–containing tissue flaps to treat lymphedema with intent to restore lymphatic drainage.

Outcome differencesMeta-analyses show VLNT often yields greater clinical improvement than LVA; outcomes depend on donor flap selection and patient factors.

Guidance summaryProfessional guidelines (AAPS, ISL) support VLNT in selected patients at experienced centers but note evidence limitations and that VLNT is not curative.

1019T	Lymphovenous bypass, including robotic assistance, when performed, per extremity.
15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy.
15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh.
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg.
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip.
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock.
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm.
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand.
15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad.
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area.

OpenPayer

Surgery for the Prevention and Treatment of Lymphedema (for Ohio Only)

Coverage Criteria and Determinations

Applicable Codes and Coding Notes

Prior Authorization, Documentation, and Provider Requirements

Clinical Background

Definitions and Terminology

Policy Revision History and Material Changes